Compare Citius Pharmaceuticals Inc (CTXR) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SMX Security Matters plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while SMX Security Matters plc trades at $16.48 (market cap $17.04M). The key difference: Citius Pharmaceuticals Inc is the larger of the two by market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| CTXR | SMX | |
|---|---|---|
Market Cap | $20.01M | $17.04M |
Sector | Health | Technology |
52-Week High | $1.82 | $103.71K |
52-Week Low | $0.48 | $12.87 |
Enterprise Value | $16.23M | -$14.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
SMX trades at $16.45, up 4.11% today, amid a reverse stock split effective June 1, 2026. The stock shows bearish technical signals with support at $16 and resistance at $17. Financially, the company reported a net loss of $169.18 million for 2025, with negative ROE and ROA, though it strengthened its balance sheet with $77 million in financing in 2026. Recent news highlights SMX's focus on recycled plastic verification and commercialization strategies.
The outlook remains speculative; SMX's technology addresses growing demand for material traceability, but persistent losses and high cash burn pose significant risks. Investor sentiment is cautious due to weak profitability, though institutional financing provides near-term liquidity. The stock's viability hinges on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
